Literature DB >> 11431326

Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging.

Y Mardor1, Y Roth, Z Lidar, T Jonas, R Pfeffer, S E Maier, M Faibel, D Nass, M Hadani, A Orenstein, J S Cohen, Z Ram.   

Abstract

Convection-enhanced drug delivery (CEDD) is a novel approach to enhance the delivery of drugs directly into brain tumors. We have used diffusion-weighted MRI (DWMRI) to monitor the effects of intratumoral CEDD in three brain tumor patients treated with Taxol. Clear changes in the images and the water diffusion parameters were observed shortly after the initiation of treatment. Initially, a bright area corresponding to decreased diffusion appeared, followed by the appearance of a dark area of increased diffusion within the bright area. The time to appearance of the dark area varied among the patients, suggesting different response rates. In this work, we have demonstrated the feasibility of using DWMRI as a noninvasive tool to achieve unique early tissue characterization not attainable by other conventional imaging methods.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11431326

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  79 in total

1.  Ultrasound-enhanced drug transport and distribution in the brain.

Authors:  Ying Liu; Sumit Paliwal; Krystof S Bankiewicz; John R Bringas; Gill Heart; Samir Mitragotri; Mark R Prausnitz
Journal:  AAPS PharmSciTech       Date:  2010-06-08       Impact factor: 3.246

2.  Convection-enhanced delivery catheter placements for high-grade gliomas: complications and pitfalls.

Authors:  Tal Shahar; Zvi Ram; Andrew A Kanner
Journal:  J Neurooncol       Date:  2011-11-04       Impact factor: 4.130

Review 3.  Novel delivery strategies for glioblastoma.

Authors:  Jiangbing Zhou; Kofi-Buaku Atsina; Benjamin T Himes; Garth W Strohbehn; W Mark Saltzman
Journal:  Cancer J       Date:  2012 Jan-Feb       Impact factor: 3.360

Review 4.  Applications of molecular imaging.

Authors:  Craig J Galbán; Stefanie Galbán; Marcian E Van Dort; Gary D Luker; Mahaveer S Bhojani; Alnawaz Rehemtulla; Brian D Ross
Journal:  Prog Mol Biol Transl Sci       Date:  2010       Impact factor: 3.622

5.  Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiforme.

Authors:  Inas S Khayal; Mei-Yin C Polley; Llewellyn Jalbert; Adam Elkhaled; Susan M Chang; Soonmee Cha; Nicholas A Butowski; Sarah J Nelson
Journal:  Neuro Oncol       Date:  2010-05-25       Impact factor: 12.300

Review 6.  Diffusion-weighted MRI for assessment of early cancer treatment response.

Authors:  Stefanie Galbán; Jean-Christophe Brisset; Alnawaz Rehemtulla; Thomas L Chenevert; Brian D Ross; Craig J Galbán
Journal:  Curr Pharm Biotechnol       Date:  2010-09-01       Impact factor: 2.837

7.  Integrative analysis of diffusion-weighted MRI and genomic data to inform treatment of glioblastoma.

Authors:  Guido H Jajamovich; Chandni R Valiathan; Razvan Cristescu; Sangeetha Somayajula
Journal:  J Neurooncol       Date:  2016-07-08       Impact factor: 4.130

8.  Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478.

Authors:  Bénédicte F Jordan; Matthew Runquist; Natarajan Raghunand; Amanda Baker; Ryan Williams; Lynn Kirkpatrick; Garth Powis; Robert J Gillies
Journal:  Neoplasia       Date:  2005-05       Impact factor: 5.715

9.  Convection-enhanced drug delivery of interleukin-4 Pseudomonas exotoxin (PRX321): increased distribution and magnetic resonance monitoring.

Authors:  Y Mardor; D Last; D Daniels; R Shneor; S E Maier; D Nass; Z Ram
Journal:  J Pharmacol Exp Ther       Date:  2009-05-28       Impact factor: 4.030

10.  The role of magnetic resonance imaging (MRI) in prostate cancer imaging and staging at 1.5 and 3 Tesla: the Beth Israel Deaconess Medical Center (BIDMC) approach.

Authors:  B Nicolas Bloch; Robert E Lenkinski; Neil M Rofsky
Journal:  Cancer Biomark       Date:  2008       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.